Stock Research for PGNX

PGNX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

PGNX Stock Chart & Research Data

The PGNX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PGNX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


PGNX Due diligence Resources & Stock Charts

The PGNX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PGNX Detailed Price Forecast - CNN Money CNN View PGNX Detailed Summary - Google Finance
Yahoo View PGNX Detailed Summary - Yahoo! Finance Zacks View PGNX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View PGNX Trends & Analysis - Trade-Ideas Barrons View PGNX Major Holders - Barrons
NASDAQ View PGNX Call Transcripts - NASDAQ Seeking View PGNX Breaking News & Analysis - Seeking Alpha
Spotlight View PGNX Annual Report - CompanySpotlight.com OTC Report View PGNX OTC Short Report - OTCShortReport.com
TradeKing View PGNX Fundamentals - TradeKing Charts View PGNX SEC Filings - Bar Chart
WSJ View Historical Prices for PGNX - The WSJ Morningstar View Performance/Total Return for PGNX - Morningstar
MarketWatch View the Analyst Estimates for PGNX - MarketWatch CNBC View the Earnings History for PGNX - CNBC
StockMarketWatch View the PGNX Earnings - StockMarketWatch MacroAxis View PGNX Buy or Sell Recommendations - MacroAxis
Bullish View the PGNX Bullish Patterns - American Bulls Short Pains View PGNX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View PGNX Stock Mentions - StockTwits PennyStocks View PGNX Stock Mentions - PennyStockTweets
Twitter View PGNX Stock Mentions - Twitter Invest Hub View PGNX Investment Forum News - Investor Hub
Yahoo View PGNX Stock Mentions - Yahoo! Message Board Seeking Alpha View PGNX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for PGNX - SECform4.com Insider Cow View Insider Transactions for PGNX - Insider Cow
CNBC View PGNX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PGNX - OTC Markets
Yahoo View Insider Transactions for PGNX - Yahoo! Finance NASDAQ View Institutional Holdings for PGNX - NASDAQ


Stock Charts

FinViz View PGNX Stock Insight & Charts - FinViz.com StockCharts View PGNX Investment Charts - StockCharts.com
BarChart View PGNX Stock Overview & Charts - BarChart Trading View View PGNX User Generated Charts - Trading View




Latest Financial News for PGNX


Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences — Renewed Outlook, Key Drivers of Growth
Posted on Thursday October 18, 2018

NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.


The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
Posted on Friday October 12, 2018

Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...


Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA
Posted on Thursday October 11, 2018

Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced plans to advance I-131 1095, its PSMA-targeted therapeutic, into a Phase 2 clinical study. The multicenter, randomized, controlled trial will evaluate the efficacy and safety of 1095 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who are PSMA-avid, chemotherapy naïve, and progressed on abiraterone.


Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine
Posted on Tuesday October 09, 2018

Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the Company’s pivotal trial of AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic, has been published in The Journal of Nuclear Medicine. The study entitled, “Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma,” reports the complete results of the pivotal study of AZEDRA. This trial was the largest multicenter, prospective trial to evaluate the safety and efficacy of any therapy in patients with pheochromocytoma and paraganglioma and formed the basis of AZEDRA’s approval by the U.S. Food and Drug Administration (FDA) in July 2018.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.